G. Dennis

Wilmington University — United States

Medicine · Health Sciences

23h-index4.8kcitations54works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Systemic Lupus Erythematosus Research(24), T-cell and B-cell Immunology(16), Monoclonal and Polyclonal Antibodies Research(16), Immune Cell Function and Interaction(9), Systemic Sclerosis and Related Diseases(6)

Publications54 total

Biomarkers in Clinical Trials for Rheumatoid Arthritis
2017
Homozygous Familial Hypercholesterolaemia – Summary of cases detected at the Bristol Genetics Laboratory
Atherosclerosis·2016
Modernising workflows for high throughput testing for Familial Hypercholesterolaemia: How to deliver a cost effective genetic testing service
Atherosclerosis·2016· 1 cited
カスケード7レベルインバータにおける選択的高調波除去(SHE)のスイッチング角の解析解【Powered by NICT】
IEEE Conference Proceedings·2016
Burden of corticosteroid use in patients with systemic lupus erythematosus: results from a Delphi panel
Lupus·2014· 43 cited
Impact of Early Versus Late Systemic Lupus Erythematosus Diagnosis on Clinical and Economic Outcomes
Applied Health Economics and Health Policy·2014· 98 cited
Implementation of a comprehensive gene screening test for familial hypercholesterolaemia using next generation sequencing
Atherosclerosis·2013
Clinical Practice Guideline: Improving Voice Outcomes after Thyroid Surgery
Otolaryngology·2013· 449 cited
Health care resource utilization patterns associated with belimumab in patients with systemic lupus erythematosus: Results from observe study in the United States
Value in Health·2013
Cumulative Burden of Oral Corticosteroid Adverse Effects and the Economic Implications of Corticosteroid Use in Patients With Systemic Lupus Erythematosus
Clinical Therapeutics·2013· 69 cited
Amélioration clinique précoce chez des patients atteints de lupus systémique (LS) traités par bélimumab
La Revue de Médecine Interne·2012
SAT0188 Early clinical improvement in SLE patients treated with belimumab
Annals of the Rheumatic Diseases·2012· 1 cited
SAT0448 Clinical outcomes and healthcare utilization following early versus late diagnosis of systemic lupus
Annals of the Rheumatic Diseases·2012
AB1331 The impact of systemic lupus erythematosus on employment loss from a population-based cohort
Annals of the Rheumatic Diseases·2012· 1 cited
PSY56 Impact of Early Versus Late Systemic Lupus Erythematosus (SLE) Diagnosis on Clinical and Economic Outcomes
Value in Health·2012· 1 citedOpen Access
PSY2 Adverse Event Burden, Resource Use and Costs Associated With Immunosuppressant Therapy for the Treatment of Systemic Lupus Erythematosus: A Systematic Literature Review
Value in Health·2012Open Access
Medical and Surgical Induced Abortion
InTech eBooks·2012· 2 citedOpen Access
Belimumab: A BLyS-Specific Inhibitor for the Treatment of Systemic Lupus Erythematosus
Clinical Pharmacology & Therapeutics·2011· 30 cited
Amélioration de la fatigue et la qualité de vie à 52 semaines chez les patients atteints de lupus systémique répondeurs dans les essais cliniques de phase 3 du bélimumab
La Revue de Médecine Interne·2011
PND12 the Cost of Corticosteroid-associated Adverse Events in Systemic Lupus Erythematosus
Value in Health·2011
page 1 of 3Next →

Frequent Co-authors

George C. Tsokos(6), Judith A. James(5), John B. Harley(5), C. Molta(5), J J Mond(5), Melissa R. Arbuckle(4), Micah T. McClain(4), Mark V. Rubertone(4), Edith J. Enyedy(4), Madhusoodana P. Nambiar(4), Gary M. Kammer(4), F D Finkelman(4), Stamatis‐Nick C. Liossis(3), Alan Oglesby(3), Caroline Korves(3), François Laliberté(3), Ellison Suthoff(3), Mei Sheng Duh(3), Benno Bechtel(3), Victor McMillan(3)